Supplementary Table 1 Characteristics of included literatures

Author	Public year	Location	No. of patients/pr-ocedures	No.of patients pre-treated with tirofiban	No.of patients pre-treated with DAPT	Agent	Method of Administration	Mean/Median clinical follow-up(mo)	Thromboembolic complications imaging madility	Proportion of ischemic complications due to covert strokes (MRI)
Nohra Chalouhi	2016	U.S.A	46/46	46	0	Tirofiban	Drip alone	NR	CT/MRI	NR
Xiao-dong Liang	2015	China	221/243	221	0	Tirofiban	Bolus plus drip	3	CT/MRI	NR
S.Kim	2016	Korea	41/41	41	0	Tirofiban	Bolus plus drip	0.23	CT/MRI	NR
Nohra Chalouhi,	2012	U.S.A	67/67	58	0	Tirofiban	Bolus plus drip vs drip alone	NR	MRI	0
Kaustubh Limaye	2019	U.S.A	19/25	19	0	Tirofiban	Drip alone	NR	CT	NR
Sang Hyub Lee	2018	Korea	50/51	50	0	Tirofiban	Bolus plus drip	19	CT	NR
Zi-liang Wang	2016	China	281/298	178	120	Tirofiban /ASA+clopidogrel	Bolus plus drip/ loading dose of clopidogrel+dual platelet	3	MRI	NR
Sébastien Soize	2019	France	80/80	0	80	ASA+clopidogrel/ASA+ticagrelor	Loading dose of ASA and clopidogrel over 5 days/ loading dose of ASA and ticagrelor over 2 days	3	MRI	25% in ASA and clopidogrel group; 8% in ASA and ticagrelor group
Paul M. Foreman	2018	Austria	49/53	0	49	ASA+clopidogrel	Loading dose of ASA and clopidogrel over 3 days	21.6	MRI	23%
Se Hwan Park	2012	Korea	57/64	0	57	ASA+clopidogrel	Loading dose of ASA and clopidogrel/ maintenance dose of ASA and clopidogrel over 5 days	NR	MRI	20% in loading group; 60% in maintenance group
Joseph S. Hudson	2017	U.S.A	80/80	0	32	ASA+clopidogrel	Loading dose of ASA and clopidogrel	28.8	MRI	NR
Gyojun Hwang	2010	Korea	262/328	0	167	ASA+clopidogrel	Maintenance dose of ASA and clopidogrel over 5 days	NR	MRI	NR
Elias Atallah	2017	U.S.A	398/398	0	398	ASA+clopidogrel	Loading dose of ASA and clopidogrel/ maintenance dose of ASA	15.8	MRI	NR

							and clopidogrel over 5 days			
Anthony Peret	2020	Belgium	362/400	0	362	ASA+clopidogrel	Loading dose of ASA and clopidogre	3	MRI	35%
Justin M. Moore	2017	U.S.A	103/103	0	103	ASA+clopidogrel/ASA+ticagrelor	Maintenance dose of ASA and clopidogrel for 14 days/ loading dose of ASA and ticagrelor	6	MRI	NR

Supplementary Table 2 Results of quality evaluation using the Methodological Index for Nonrandomized Studies (MINORS)

Study Reference	Public Year	Q1	Q2	Q3	Q4	Q5	Q6	Q7	Q8	Q9	Q10	Q11	Q12	Quality（scores）
Nohra Chalouhi	2016	2	2	0	2	0	0	2	0	N/A	N/A	N/A	N/A	Intermediate(8)
Xiao-dong Liang	2015	2	2	0	2	0	2	2	0	N/A	N/A	N/A	N/A	Intermediate(10)
S. Kim	2016	2	2	0	2	0	0	2	0	N/A	N/A	N/A	N/A	Intermediate(8)
Nohra Chalouhi	2012	2	2	0	2	0	0	0	0	N/A	N/A	N/A	N/A	Low(6)
Kaustubh Limaye	2019	2	2	0	2	0	0	0	0	N/A	N/A	N/A	N/A	Low(6)
Sang Hyub Lee	2018	2	2	0	2	0	2	0	0	N/A	N/A	N/A	N/A	Intermediate(8)
Zi-liang Wang	2016	2	2	0	2	0	2	2	0	0	2	2	2	Intermediate(16)
Sé bastien Soize	2019	2	2	0	2	0	2	2	0	2	0	2	2	Intermediate(16)
Paul M. Foreman	2018	2	2	0	2	0	2	2	0	N/A	N/A	N/A	N/A	Intermediate(10)
Se Hwan Park	2012	2	2	0	2	0	0	0	0	2	0	2	2	Intermediate(12)
Joseph S. Hudson	2017	2	2	0	2	0	2	2	0	2	2	0	0	Intermediate(14)
Gyojun Hwang	2010	2	2	0	2	0	0	0	0	2	0	0	2	Intermediate(10)
Elias Atallah	2017	2	2	0	2	0	2	2	0	2	2	2	2	Intermediate(18)

Anthony Peret	2020	2	2	0	2	0	2	2	0	2	2	0	2	Intermediate(16)
Justin M. Moore	2017	2	2	0	2	0	2	0	0	2	2	2	2	Intermediate(16)

Numbers 1-12 in heading signified: Q1: Did the study have a clearly stated aim? Q2: Were consecutive patients included? Q3: Were data collected prospectively? Q4: Were endpoints appropriate to the study? Q5: Was there an unbiased assessment of endpoints? Q6: Was the follow-up period adequate? Q7: Was loss to follow-up less than 5%? Q8: Was there a prospective calculation of study size? Q9: Did the study have an adequate control group? Q10: Did the study have contemporary groups? Q11: Were baseline of groups equivalent? Q12: Was there an adequate statistical analysis? 0, not reported; 1, reported but inadequate; 2, reported and adequate.

Supplementary Figure 1



Transformed cumulative incidence with “Tirofiban versus DAPT” by the first arcsine transformation via Stata. A) Transformed ES of thromboembolic complications of tirofiban group (1) and DAPT group (2). B) Transformed ES of hemorrhage complications of tirofiban group (1) and DAPT group (2). C) Transformed ES of perioperative mortality related to

antiplatelet medication of tirofiban group (1) and DAPT group (2). D) Transformed ES of good clinical outcomes of tirofiban group (1) and DAPT group (2).

Supplementary Figure 2



Transformed cumulative incidence with “Bolus dose plus drip of tirofiban versus drip alone” by the first arcsine transformation via Stata.A) Transformed ES of thromboembolic complications of bolus dose plus drip of tirofiban group (1) and drip group (2) . B) Transformed ES of hemorrhage complications of bolus dose plus drip of tirofiban group (1) and drip group (2). C) Transformed ES of perioperative mortality related to antiplatelet medication of bolus dose plus drip of tirofiban group (1) and drip group (2). D) Transformed ES of good clinical outcomes of bolus dose plus drip of tirofiban group (1) and drip group (2).

Supplementary Figure 3



Transformed cumulative incidence with “ASA+clopidogrel versus ASA+ticagrelor” by the first arcsine transformation via Stata.A) Transformed ES of thromboembolic complications of ASA+clopidogrel group (1) and ASA+ticagrelor group (2). B) Transformed ES of hemorrhage complications of ASA+clopidogrel group (1) and ASA+ticagrelor group (2). C) Transformed ES of perioperative mortality related to antiplatelet medication of ASA+clopidogrel group (1) and ASA+ticagrelor group (2). D) Transformed ES of good clinical outcomes of ASA+clopidogrel group (1) and ASA+ticagrelor group (2).